1011 related articles for article (PubMed ID: 33524400)
21. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
22. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
Mandelker D; Marra A; Zheng-Lin B; Selenica P; Blanco-Heredia J; Zhu Y; Gazzo A; Wong D; Yelskaya Z; Rai V; Somar J; Ostafi S; Mehta N; Yang C; Li Y; Brown DN; da Silva EM; Pei X; Linkov I; Terraf P; Misyura M; Ceyhan-Birsoy O; Ladanyi M; Berger M; Pareja F; Stadler Z; Offit K; Riaz N; Park W; Chou J; Capanu M; Koehler M; Rosen E; O'Reilly EM; Reis-Filho JS
J Clin Oncol; 2023 Nov; 41(33):5151-5162. PubMed ID: 37607324
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
24. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Chen KT; Madison R; Moore J; Jin D; Fleischmann Z; Newberg J; Schrock A; Bhardwaj N; Lofgren KT; He J; Frampton G; Hegde P; Fabrizio D; Pishvaian MJ; Ebot E; Singhi A; Sokol E
Oncologist; 2023 Aug; 28(8):691-698. PubMed ID: 37354528
[TBL] [Abstract][Full Text] [Related]
25. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract][Full Text] [Related]
26. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
27. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
[TBL] [Abstract][Full Text] [Related]
28.
Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
[TBL] [Abstract][Full Text] [Related]
29. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
30. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
31. Pan-cancer landscape of homologous recombination deficiency.
Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract][Full Text] [Related]
33. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
[TBL] [Abstract][Full Text] [Related]
35. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
36. Molecular analysis of PALB2-associated breast cancers.
Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
[TBL] [Abstract][Full Text] [Related]
37. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.
Yadav S; Kasi PM; Bamlet WR; Ho TP; Polley EC; Hu C; Hart SN; Rabe KG; Boddicker NJ; Gnanaolivu RD; Lee KY; Lindstrom TH; Petersen GM; Couch FJ; McWilliams RR
Clin Cancer Res; 2020 Dec; 26(24):6505-6512. PubMed ID: 33028596
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
39. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
Boeck S; Mehraein Y; Ormanns S; Kruger S; Westphalen CB; Haas M; Jung A; Kirchner T; Heinemann V
Ann Oncol; 2017 Feb; 28(2):438-439. PubMed ID: 27803004
[No Abstract] [Full Text] [Related]
40. The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.
Štancl P; Hamel N; Sigel KM; Foulkes WD; Karlić R; Polak P
Front Genet; 2022; 13():852159. PubMed ID: 35783256
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
